Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Citius Pharmaceuticals Inc (CTXR)

Citius Pharmaceuticals Inc (CTXR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,570
  • Shares Outstanding, K 22,376
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,430 K
  • EBIT $ -37 M
  • EBITDA $ -37 M
  • 60-Month Beta 1.38
  • Price/Sales 3.05
  • Price/Cash Flow N/A
  • Price/Book 0.19
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.45
  • Most Recent Earnings $-0.38 on 02/13/26
  • Next Earnings Date 05/13/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 355.53% (+106.72%)
  • Historical Volatility 127.75%
  • IV Percentile 74%
  • IV Rank 34.04%
  • IV High 930.28% on 12/09/25
  • IV Low 58.96% on 01/20/26
  • Expected Move (DTE 8) 1.4110 (170.02%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 64
  • Volume Avg (30-Day) 225
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 5,173
  • Open Int (30-Day) 5,273
  • Expected Range 0.0000 to 2.2409

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-1.50
  • Growth Rate Est. (year over year) +66,700.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6702 +23.83%
on 03/30/26
1.0750 -22.80%
on 03/11/26
-0.0052 (-0.62%)
since 03/06/26
3-Month
0.6500 +27.68%
on 02/23/26
1.0750 -22.80%
on 03/11/26
-0.0701 (-7.79%)
since 01/08/26
52-Week
0.6300 +31.73%
on 12/24/25
2.4800 -66.54%
on 07/03/25
-0.1501 (-15.32%)
since 04/08/25

Most Recent Stories

More News
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integration

CTXR : 0.8299 (+5.18%)
CTOR : 0.6422 (-3.27%)
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts

Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinical engagement; one-on-one meetings available

CTXR : 0.8299 (+5.18%)
CTOR : 0.6422 (-3.27%)
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy

CTXR : 0.8299 (+5.18%)
CTOR : 0.6422 (-3.27%)
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program

Non-dilutive capital supports continued execution and value creation

CTXR : 0.8299 (+5.18%)
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results

CTXR : 0.8299 (+5.18%)
CTOR : 0.6422 (-3.27%)
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar

Third international distribution agreement further advances global access strategy with major markets in Europe

CTXR : 0.8299 (+5.18%)
CTOR : 0.6422 (-3.27%)
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025

CTXR : 0.8299 (+5.18%)
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025

CTXR : 0.8299 (+5.18%)
CTOR : 0.6422 (-3.27%)
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Proceeds strengthen cash position and support commercial launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL)

CTXR : 0.8299 (+5.18%)
CTOR : 0.6422 (-3.27%)
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE

CTXR : 0.8299 (+5.18%)
CTOR : 0.6422 (-3.27%)

Business Summary

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 0.9815
2nd Resistance Point 0.9352
1st Resistance Point 0.8826
Last Price 0.8299
1st Support Level 0.7837
2nd Support Level 0.7374
3rd Support Level 0.6848

See More

52-Week High 2.4800
Fibonacci 61.8% 1.7733
Fibonacci 50% 1.5550
Fibonacci 38.2% 1.3367
Last Price 0.8299
52-Week Low 0.6300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.